Press Release

Printer Friendly VersionView printer-friendly version << Back



Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results

-- Management to host conference call at 4:30 p.m. EDT on March 12, 2019 --

NEWARK, Calif., March 5, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and year end 2018 financial results after the NASDAQ market closes on Tuesday, March 12, 2019. Protagonist management will host a year end update call at 4:30 p.m. EDT/1:30 p.m. PDT the same day.

Conference Call and Webcast Information

Protagonist executives will host a conference call at 4:30 p.m. EDT/1:30 p.m. PDT on Tuesday, March 12, 2019. To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 9688334. The call will also be webcast and will be accessible from "Events & Presentations" in the Investors section of the company's website at www.protagonist-inc.com. A replay will be available on the company's website approximately two hours after the call and will remain available for 60 days.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic for the potential treatment of anemia and iron overload related to rare blood diseases with an initial focus on beta thalassemia. PTG-200 is an oral peptide interleukin-23 receptor antagonist in development for the treatment of Crohn's disease. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development for the treatment of inflammatory bowel disease.

Protagonist is headquartered in Newark, California, with pre-clinical and clinical staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-announce-fourth-quarter-and-full-year-2018-financial-results-300806515.html

SOURCE Protagonist Therapeutics, Inc.

Solebury Trout, Rich Allan (media), Tel: +1 646-378-2958, Email: rallan@troutgroup.com; or Marcy Nanus (investors), Tel: +1 646-378-2927, Email: mnanus@soleburytrout.com